Literature DB >> 10942056

Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.

C Haioun1, C Besson, E Lepage, C Thieblemont, D Simon, C Rose, H Tilly, A Sonet, P Lederlin, M Attal, J Brière, F Reyes.   

Abstract

BACKGROUND: Incidence of central nervous system (CNS) recurrence in patients with aggressive non-Hodgkin's lymphoma who did not receive meningeal prophylaxis is about 5%. Controversy remains regarding risk factors associated with such an event preventing a rational approach of prophylactic strategies. PATIENTS AND METHODS: We analyzed a cohort of 974 patients with aggressive lymphoma in complete remission (CR). All the patients received a CNS prophylaxis consisting of intrathecal injections and intravenous high-dose methotrexate. The risk repartition on the basis of the international prognostic index (IPI) of these 974 CR-patients was low (L): 41%, low-intermediate (LI): 27%, high-intermediate (HI): 19%, high (H): 13%.
RESULTS: The incidence of isolated CNS relapse was 1.6%. In a first multivariate logistic regression analysis an increased LDH (P = 0.05, RR = 5) and the presence of more than one extranodal site (P = 0.05, RR = 3) were identified as independent risk factors for isolated CNS relapse. Another multivariate analysis incorporating IPI as a unique parameter showed that only IPI remained significantly associated with a higher risk of CNS relapse (L-LI: 0.6% vs. HI H: 4.1%, P = 0.002; RR = 7).
CONCLUSION: Prophylaxis notably reduces the risk of CNS recurrence in the higher risk patients. By contrast, we propose the deletion of prophylactic intrathecal injections in the lower risk patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942056     DOI: 10.1023/a:1008394827806

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  40 in total

1.  My treatment approach to patients with diffuse large B-cell lymphoma.

Authors:  James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 2.  Metastatic neurologic complications of non-Hodgkin's lymphoma.

Authors:  Jeanine Grier; Tracy Batchelor
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

3.  Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

Authors:  Steven H Bernstein; Joseph M Unger; Michael Leblanc; Jonathan Friedberg; Thomas P Miller; Richard I Fisher
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

4.  CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission.

Authors:  Vittorio Stefoni; Alessandro Broccoli; Cinzia Pellegrini; Enrico Derenzini; Mariapaola Fina; Pier Luigi Zinzani
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

5.  Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C.

Authors:  Marc C Chamberlain; Sandra K Johnston; Alixis Van Horn; Michael J Glantz
Journal:  J Neurooncol       Date:  2008-09-27       Impact factor: 4.130

Review 6.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

Authors:  Ching-Hon Pui; Eckhard Thiel
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

7.  Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.

Authors:  Gandhi Damaj; Sarah Ivanoff; Diane Coso; Loïc Ysaebert; Sylvain Choquet; Caroline Houillier; Anne Parcelier; Wajed Abarah; Zora Marjanovic; Rémy Gressin; Reda Garidi; Momar Diouf; Anne-Claire Gac; Jehan Dupuis; Xavier Troussard; Franck Morschhauseur; Hervé Ghesquières; Carole Soussain
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

8.  Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center.

Authors:  Agustin Avilés; M Jesús Nambo; Natividad Neri
Journal:  Med Oncol       Date:  2013-03-01       Impact factor: 3.064

9.  Treatment of primary intraocular lymphoma with intravitreal methotrexate.

Authors:  Reika Sou; Nobuyuki Ohguro; Tetsuo Maeda; Yoshitsugu Saishin; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2008-07-27       Impact factor: 2.447

10.  Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience.

Authors:  Yutaka Shimazu; Kenji Notohara; Yasunori Ueda
Journal:  Int J Hematol       Date:  2009-04-09       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.